MedTrace Logo

Letrozole as a Prophylaxis From GTN for Complete Mole Patients

NCT05203562 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2022-07-12

No results posted yet for this study

Summary

Prophylactic use of aromatase inhibitor is effective in decreasing the incidence of Gestational Trophoblastic Neoplasia (GTN) in patients with complete hydatidiform mole (CHM)

Conditions

  • Gestational Trophoblastic Disease

Interventions

PROCEDURE

Suction evacuation

both groups underwent complete mole evacuation using suction curettage.

DRUG

Letrozole tablets

Group II Patients received 5mg(2tablets 2.5gm) daily letrozole for 10 days after complete mole evacuation

Sponsors & Collaborators

  • Zagazig University

    lead OTHER_GOV

Principal Investigators

  • Mohamed A Alabiad, MD · Zagazig University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2022-12-01
Completion
2023-06-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05203562 on ClinicalTrials.gov